Retail Sales Figures - DOC

Document Sample
Retail Sales Figures - DOC Powered By Docstoc
					                                              Table 31
                                               Misc

1.   Retail sales figures for UNAPPROVED USE of the quinolones
     http://161.188.204.190/krdigital/drug/
               Cipro
               Drug class: Quinolone antibiotics
               Company: Bayer AG
               Total retail sales:
               $963 million
               Approved uses: Urinary tract infections, acute uncomplicated cystitis in females, chronic
               bacterial prostatitis, lower respiratory tract infections, acute sinusitis, skin infections,
               bone and joint infections, complicated intra-abdominal infections, infectious diarrhea,
               Thyphoid fever (enteric fever), uncomplicated cervical and urethral gonorrhea,
               inhalational anthrax

              Prescriptions for approved uses 8.1 million (70%)
              Unapproved uses include: Diverticulitis of colon, chronic/unspecified sinusitis, ear
              infections, unspecified abdominal pain
              Prescriptions for unapproved uses 3.5 million (30%)
              Retail sa les for unapproved uses:
              $291 million

              FDA prescribing information.
              Levaquin
              Drug class: Quinolone antibiotics
              Company: Johnson & Johnson
              Total retail sales:
              $1,068 million
              Approved uses: Acute maxillary sinusitis, pneumonia, skin infections, chronic bacterial
              prostatitis, urinary tract infections, acute pyelonephritis, acute bacterial exacerbation of
              chronic bronchitis, all caused by certain specified bacteria
              Prescriptions for approved uses 7.1 million (58%)
              Unapproved uses include: Chronic/unspecified sinusitis, ear infections, cough, asthmatic
              bronchitis
              Prescriptions for unapproved uses 5.1 million ( 42%)
              Retail Sales for unapproved uses;
              $446 million

              FDA prescribing information.
              Avelox
              Drug class: Quinolone antibiotics
              Company: Bayer AG
              Total retail sales:
              $227 million
              Approved uses: Acute bacterial sinusitis, acute bacterial exacerbations of chronic
              bronchitis, community acquired pneumonia, uncomplicated skin infections
              Prescriptions for approved uses 1.2 million (44%)
              Unapproved uses include: Chronic/unspecified sinusitis, ear infections, cough, sore throat
              Prescriptions for unapproved uses 1.5 million (56%)
              Retail sales for unapproved uses:
              $128 million




                                                   1
               Source: Knight Ridder analysis of prescribing data by Verispan's Physician Drug and
               Diagnosis Audit and its Source Prescription Audit. Prescription data is for the year
               ending July 31, 2003

2.    Of 100 total patients, 81 received an FQ for an inappropriate
      indication. Of the 19 patients who received an FQ for an appropriate indication, only 1 received
      both the correct dose and duration of therapy. ( Only 1% received the appropriate drug at the
      appropriate dose, hence 99% of the prescriptions were in error)
      Fluoroquinolone Utilization in the Emergency Departments of Academic
      Medical Centers
      Prevalence of, and Risk Factors for, Inappropriate Use
      Ebbing Lautenbach, MD, MPH; Lori A. Larosa, PharmD; Nishaminy
      Kasbekar, PharmD; Helen P. Peng, PharmD; Richard J. Maniglia, MD;
      Neil O. Fishman, MD
      Arch Intern Med.2003;163:601-605.

3.    Quotes from a recent FDA hearing regarding approval of Moxifloxacin (Avelox) a
      fluoroquinolone (See Attachemnt GG)

4.    Division of Special Pathogen and Immunologic Drug Products
      Summary of Clinical Review of Studies Submitted in Response to a Pediatric Written Request
      Applications: 19-537/S-049, ciprofloxacin tablets
      20-780/S-013, ciprofloxacin oral suspension
      19-847/S-027, ciprofloxacin IV 10 mg/mL
      19-857/S-031, ciprofloxacin IV 5% dextrose
      Applicant: Bayer Corporation, Pharmaceutical Division
      Established: Ciprofloxacin

5.    Center for Drug Evaluation and Research Approval Package for Levaquin NDA 20-635

6.    Center for Drug Evaluation and Research Approval Package for Levaquin NDA 020-634/S04 and
      020635/S03

7.    Excerpts from 62nd meeting of the Anti-Infective Drugs Advisory Committee
      (See Attachment HH) Wednesday, November 19, 1997

8.    FDA Briefing Package
      (Gemifloxacin) Anti-Infective Drugs Advisory Committee (March 4, 2003) New Drug
      Application (NDA) 21-158 Factive (gemifloxacin mesylate)

9.    Department Of Health and Human Services Food and Drug Administration Center for Drug
      Evaluation and Research Pediatric Advisory Subcommittee of the Anti-Infective Drugs Advisory
      Committee Wednesday, June 9, 2004

10.   LEVAQUIN® (levofloxacin) Presentation to AIDAC October 20, 1999 ... 12/1/99. Click here to
      start. Table of Contents. LEVAQUIN® (levofloxacin) Presentation to AIDAC October 20, 1999.
      FDA Approval: December 20, 1996..
      http://www.fda.gov/ohrms/dockets/ac/99/slides/3558s1d/

11.   020634s04 Levaquin (Levofloxacin) Tablets & Injection Levaquin (Levofloxacin) Tablets &
      Injection Company: RW Johnson Application No.: 020634/S04 & 0202635/S03 Approval Date:
      12/17/1998.
      http://www.fda.gov/cder/foi/nda/98/020634s04.htm




                                                  2
12.   FDA Drug Approvals List September 2000
      08-SEP-00 Trade Name: LEVAQUIN Dosage Form: TABLET Applicant ... To Original New
      Drug Application Approval Date: 01-SEP-00 ... 08, 2001 http://www.fda.gov/cder/da/da0900.htm

13.   FDA Drug Approvals List December 1998
      ... 17-DEC-98 Trade Name: LEVAQUIN Dosage Form: TABLET Applicant ... Original New
      Drug Application
      Approval Date: 01-DEC-98 ... 19., 1999 http://www.fda.gov/cder/da/da1298.htm

14.   FDA Drug Approvals List February 2000
      ... 02-FEB-00 Trade Name: LEVAQUIN Dosage Form: TABLET Applicant ... To Original New
      Drug
      Application Approval Date: 02-FEB-00 ... 08, 2001 http://www.fda.gov/cder/da/da0200.htm

15.   NDA 20-634/S-008, S-009 NDA 20-635/S-007, S-008 The RW ...
      ... for LEVAQUIN Tablets and LEVAQUIN Injection. We acknowledge receipt of ... S-007, S-
      008." Approval of these submissions by FDA is not required before ...
      http://www.fda.gov/cder/foi/appletter/2000/20635S7,8LTR.PDF

16.   Reference Listed Drug Labeling Approved in December 2001
      ... levofloxacin tablets, 20-635. S-020. LEVAQUIN, letter, label, levofloxacin injection, ...
      Approval Date, Trade Name. Active Ingredient(s ... FDA/Center for Drug Evaluation and ...
      http://www.fda.gov/cder/ogd/rld/rld_labeling_approved_dec
      _2001.htm

17.   DEPARTMENT OF HEALTH & HUMAN SERVICES NDA 20-634/S-025 NDA 20 ...
      ... provide for the use of Levaquin Tablets and Injection for the ... NDA 20-635/S-022." Approval
      of these submissions by FDA is not required before the ...
      http://www.fda.gov/cder/foi/appletter/
      2002/20634se1-025,20635se1-022ltr.pdf

18.   Application Number : 020635 Trade Name : LEVAQUIN INJECTION ... ... Number : 020635
      Trade Name : LEVAQUIN INJECTION Generic Name: Levofloxacin ... approved NDA 20-635.
      Approval of this submission ~ FDA is not required before ...
      http://www.fda.gov/cder/foi/nda/96/020635ap.pdf

19.   Reference Listed Drug Labeling Approved in September 2000
      ... approved labeling or the supplemental approval letter describing the specific changes ...
      LEVAQUIN, levofloxacin injection, 20-635/S ... FDA/Center for Drug Evaluation and ...
      http://www.fda.gov/cder/ogd/rld/rld_labeling_approved_september_2000.html


20.   NDA 20-634/S-013 NDA 20-635/S-010 The RW Johnson ...
      ... provide for the use of LEVAQUIN ® for the treatment of complicated ... NDA 20-635/S-010."
      Approval of these submissions by FDA is not required before ...
      http://www.fda.gov/cder/foi/appletter/2000/20635S10ltr.pdf

21.   Reference Listed Drug Labeling Approved in February 2000
      ... approved labeling or the supplemental approval letter describing the specific ... Johnson RW, 2.
      LEVAQUIN, Levofloxacin tabs, 20-634/S ... FDA/Center for Drug Evaluation ...
      http://www.fda.gov/cder/ogd/rld/RLD_LABEL_APPROVED
      _FEB_2000.HTML




                                                   3
22.   DEPARTMENT OF HEALTH & HUMAN SERVICES ...
      ... the following changes to the Levaquin ® pakage insert. The deleted text ... S-019, S-020."
      Approval of these submissions by FDA is not required before ...
      http://www.fda.gov/cder/foi/appletter/2001/20634s15s21s22ltr.pdf

23.   Drug Approvals - L
      Product Name, Company, Application #, Approval Date, Letter Posted. Label Posted, Review
      Posted. ... Levaquin, Rx, RW Johnson, NDA 20-634, S004 & 20-635, S003, 12/17 ...
      http://www.fda.gov/cder/approval/l.htm

24.   RLD_LABELING_APPROVED_JUL_1999
      ... labeling or the supplemental approval letter describing the specific ... 29-Jul-1999.
      LEVAQUIN, Levofloxacin tablets, 20-634. S ... [http://www.fda.gov/cder/cderbar.htm]. ...
      http://www.fda.gov/cder/ogd/rld/RLD_LABELING_APPROVED
      _JUl_1999.HTML

25.   Reference Listed Drug Labeling Approved in October 2002
      ... Approval. Date. Product Name. Source Documents, Active ... Oct 30, LEVAQUIN, letter, label,
      levofloxacin injection, 20-635, SE1 ... FDA/Center for Drug Evaluation and Research ...
      http://www.fda.gov/cder/ogd/rld/rld_labeling_approved
      _october_2002.htm

26.   NDA 20-634/S-015, S-021, S-022 NDA 20-635/S-012, S-019, S-020 ... ... the following changes
      to the Levaquin ® pakage insert. The deleted text ... S-019, S-020." Approval of these submissions
      by FDA is not required before ...
      http://www.fda.gov/cder/foi/appletter/2001/20365s20ltr.pdf

27.   Drug Approvals December 1996
      ... 20-DEC-96 Trade Name: LEVAQUIN Chemical Type: 3 Therapeutic ... To Original New Drug
      Application
      Approval Date: 03-DEC-96 ... 1, 1997 http://www.fda.gov/cder/da/da1296.htm

28.   1996 and Older - New Drug Application (NDA)
      ... These drug approval packages, sorted by product ... the product name to view the approval
      packages in Adobe Acrobat format. For ... Levaquin/Levofloxacin Part 1 [8 MB ...
      http://www.fda.gov/cder/foi/nda/index96.htm

29.   Efficacy Supplements Approved in Calendar Year 2003 (SE1-SE7 ... ... GENERIC NAME,
      APPLICANT, NDA NUMBER, ... DATE, PRIORITY REVIEW, TOTAL APPROVAL TIME
      (MONTHS),
      INDICATION/DESCRIPTION. ... for the use of Levaquin Tablets for the treatment of ...
      http://www.fda.gov/cder/rdmt/ESCY03AP.HTM

30.   Tequin Consumer Information
      ... Approved by FDA: December 17, 1999. *Approval by FDA does not mean that the ... such as
      Cipro (ciprofloxacin) or Levaquin (levofloxacin). have a rare condition ...
      http://www.fda.gov/cder/consumerinfo/druginfo/tequin.htm

31.   Efficacy Supplements Approved in Calendar Year 2002 (SE1-SE7 ... ... GENERIC NAME,
      APPLICANT, NDA NUMBER, SUPP ... 02 **, 10.6, Provides a tentative approval
      for the use of Follistim ... for the use of Levaquin Tablets for the treatment of ...
      http://www.fda.gov/cder/rdmt/ESCY02AP.HTM




                                                   4
32.   September 2000 Safety-Related Drug Labeling Changes
      /... CHANGES APPROVED BY FDA September 2000. ... flush), LAMICTAL (lamotrigene),
      LEVAQUIN (levofloxacin), LUVOX (fluvoxamine ... identified during post-approval use of
      Flolan ...
      http://www.fda.gov/medwatch/safety/2000/sep00.htm

33.   Developing Drugs for Resistant Pathogens
      ... Table 3 (cont.) October 1999 Levaquin (levofloxacin) IV/PO Penicillin ... survival or
      irreversible morbidity. FDA may grant marketing approval for a new drug ...
      http://www.fda.gov/ohrms/dockets/ac/02/briefing/
      3837b2_01_Resistance.pdf

34.   EFFICACY SUPPLEMENTS APPROVED IN CY 2000
      ... GENERIC NAME, APPLICANT, NDA NUMBER, ... SUPP NUMBER, PRIORITY
      REVIEW, TOTAL APPROVAL
      TIME (MONTHS), INDICATION/DESCRIPTION. ... for the use of LEVAQUIN for the
      treatment of ...
      http://www.fda.gov/cder/rdmt/esap2000.htm

35.   Resistance Outline
      ... Levaquin. ... FDA may grant marketing approval for a new drug product on the basis of
      adequate and well-controlled clinical trials establishing that the drug ...
      http://www.fda.gov/ohrms/dockets/ac/02/briefing/
      3837b2_01_Resistance.doc

36.   MedWatch - October 2002 Safety-Related Drug Labeling Changes
      ... Labeling provides for the use of Levaquin Tablets and Injection for the treatment ... not in 2002
      PDR: http://www.fda.gov/medwatch/SAFETY/2002/oct02.htm

37.   This transcript has not been edited corrected, but appears ...
      ... Questions to the Advisory Committee . . LEVAQUIN Public Comment: Dr. David Bell . . . . .
      FDA Introduction, Mark Goldberger, MD CDC Presentation ...
      http://www.fda.gov/ohrms/dockets/ac/99/transcpt/3558t1a.pdf

38.   Document Information Page
      ... NDA 21-061/S-007, NDA 21-062/S-006, NDA 21-062/S-007, and NDA 21-062/S-008."
      Approval of these submissions by FDA is not required before the labeling is used. ...
      http://www.fda.gov/cder/foi/label/2001/21062s8lbl.pdf

39.   NDA 20-634/S-013 NDA 20-635/S-010 The RW Johnson ...
      ... provide for the use of LEVAQUIN ® for the treatment of complicated ... NDA 20-635/S-010."
      Approval of these submissions by FDA is not required before ...
      http://www.fda.gov/cder/ogd/rld/20635s10.pdf

40.   1 back to the other point though. If you had two ...
      Page 1. 1 back to the other point though ... www.nealrgross.com
      Page 2. 1 2 3 4 ...
      http://www.fda.gov/ohrms/dockets/ac/99/transcpt/3558t1b.pdf

41    .1 .FOOD AND DRUG ADMINISTRATION CENTER FOR DRUG ...
      ... Women's Health Project. I'm a consumer representative guest. 7 With respect to FDA's invited
      guests and guest speakers, Dr. Gideon Koren and Ms. Julia Scott ...
      http://www.fda.gov/ohrms/dockets/ac/00/transcripts/3645t1.pdf




                                                   5
42.   1 comments about it, but certainly we are interested in ...
      ... makes sense is based on two things: one, that the overall resistance to Levaquin is very low; and
      the other, that Levaquin resistance and penicillin resistance ...
      http://www.fda.gov/ohrms/dockets/ac/99/transcpt/3558t1d.pdf

43.   EXECUTIVE SUMMARY
      ... FDA Briefing Package - January 8, 2003 AIDAC meeting. NDA ... on February 28, 2000. The
      Applicant requested approval for marketing of telithromycin in the United ...
      http://www.fda.gov/ohrms/dockets/ac/03/briefing/3919B1_02_B-FDA%20Master%20Copy.pdf

44.   EXECUTIVE SUMMARY
      ... 2002 NDA Amendment, 4 of which were those recommended by the FDA in the June 2001
      approval letter. The following is a summary of the clinical pharmacology / PK ...
      http://www.fda.gov/ohrms/dockets/ac/03/briefing/3919B1_02_B-FDA%20Master%20Copy.htm

45.   EXECUTIVE SUMMARY
      ... 2002 NDA Amendment, 4 of which were those recommended by the FDA in the June 2001
      approval letter. The following is a summary of the clinical pharmacology / PK ...
      http://www.fda.gov/ohrms/dockets/ac/03/briefing/3919B1_02_B-FDA%20Master%20Copy.doc

46.   FOOD AND DRUG ADMINISTRATION. CENTER FOR ... a few months later the FDA action
      letter that followed asking ... when we're considering drug approval, and that is safety. ...
      http://www.fda.gov/ohrms/dockets/ac/03/transcripts/3919T1.doc

47.   ... FOOD AND DRUG ADMINISTRATION. CENTER ...
      a few months later the FDA action letter that
      followed asking ... when we're considering drug approval, and that is safety. ...
      http://www.fda.gov/ohrms/dockets/ac/03/transcripts/3919T1.htm

48.   ... The sponsor is requesting approval for the use of LEVAQUIN (Ievofloxacin) tablets for the ...
      Protocol M92-040: For FDA clinically evaluable patients, clinical ...
      http://www.fda.gov/cder/foi/nda/96/020634-4.pdf

49.   somebody either walks into the clinician's office with a ...
      Page 1. 1 2 3 4 somebody either walks into ... 3701 www.nealrgross.com Page 2. 1 add to our ...
      http://www.fda.gov/ohrms/dockets/ac/99/transcpt/3558t1c.pdf

50.   ... LEVAQUIN. Public Comment: Dr. David Bell ... This concept is described in FDA
      Modernization
      Act, and also ... maybe if we have approval for other serious infections or ...
      http://www.fda.gov/ohrms/dockets/ac/99/transcpt/3558t1.rtf

51.   Untitled
      ... Drug, and Cosmetic Act for Levaquin" (levofloxacin) 250- and 500- mg ... for approved
      NDA 20-634. Approval of t.hk submission by.FDA is not required before the ...
      http://www.fda.gov/cder/foi/nda/96/020634-1.pdf

52.   FDA Briefing Package
      http://www.fda.gov/ohrms/dockets/ac/01/briefing/
      3746b_02_FDA.htm
      1 DEPARTMENT OF HEALTH AND HUMAN SERVICES
      ... have 19 some additional interaction between FDA, IDSA and 20 PhRMA. The feeling ...
      additional
      6 discussion on standards for approval of new 7 products, a ...
      http://www.fda.gov/ohrms/dockets/dockets/02n0461/02n-0461-tr00001-vol3.pdf




                                                   6
53.   FDA Briefing Package
      ... Efficacy: The applicant has requested approval for telithromycin in adults for ... and
      sinusitis. Requests to the FDA regarding marketing claims for infections ...
      http://www.fda.gov/ohrms/dockets/ac/03/briefing/3919B1_02_C-FDA%20Appendix%20A.pdf

54.   FDA Briefing Package
      ... Efficacy: The applicant has requested approval for telithromycin in adults for ... and sinusitis.
      Requests to the FDA regarding marketing claims for infections ...
      http://www.fda.gov/ohrms/dockets/ac/01/briefing/
      3746b_02_FDA.pdf

55.   SAG CORP. 1 UNITED STATES OF AMERICA FOOD AND DRUG ...
      ... July meeting 16 was a meeting between FDA and largely with industry to 17 get ... beginning
      with Synercid in 16 1998, Levaquin in October of '99, Zyvox in ...
      http://www.fda.gov/ohrms/dockets/ac/02/transcripts/3837t2.pdf

56.   FDA Briefing Package
      ... Efficacy: The applicant has requested approval for telithromycin in adults for the ... Requests to
      the FDA regarding marketing claims for infections due to ...
      http://www.fda.gov/ohrms/dockets/ac/03/briefing/3919B1_02_C-FDA%20Appendix%20A.doc

57.   FDA Briefing Package
      ... Efficacy: The applicant has requested approval for telithromycin in adults for the ... Requests to
      the FDA regarding marketing claims for infections due to ...
      http://www.fda.gov/ohrms/dockets/ac/03/briefing/3919B1_02_C-FDA%20Appendix%20A.htm

58.   1 FOOD AND DRUG ADMINISTRATION CENTER FOR DRUG EVALUATION ...
      ... of 2001, a few months later the FDA action letter that 1 followed asking for ... equation
      when we're considering drug approval, 23 and that is safety. 24 ...
      http://www.fda.gov/ohrms/dockets/ac/03/transcripts/3919T1.pdf
      ... of Drug Evaluation for the FDA. Gary. ... 99 to discuss supplemental application for
      Levaquin for the treatment of penicillin ... this sponsor is requesting approval. ...
      http://www.fda.gov/ohrms/dockets/ac/00/transcripts/3597t1.rtf

59.   ... with Synercid in 1998, Levaquin in October of '99 ... early consultation between the
      FDA and pharmaceutical sponsors as ... provides for earlier approval in the drug ...
      http://www.fda.gov/ohrms/dockets/ac/02/transcripts/3837t2.doc
      ... with Synercid in 1998, Levaquin in October of '99 ... early consultation between the
      FDA and pharmaceutical sponsors as ... provides for earlier approval in the drug ...
      http://www.fda.gov/ohrms/dockets/ac/02/transcripts/3837t2.htm

60.   Ciprofloxacin Anthrax Approval; FDA Medical Review PDF FILE

61.   FDA Warning Letter Pfizer RE: Trovan Failure to disclose PDF FILE

62.   FDA Warning Letter Pfizer RE: Trovan Misleading Advertisements PDF FILE

63.   FDA Warning Letter Pfizer RE: Trovan Misleading Advertisements that fail to reveal life
      threatening risk PDF FILE

64.   FDA Warning Letter Bayer RE: Cipro Misleading
      promotional labeling PDF FILE

65.   FDA Warning Letter Bayer RE: Cipro Violative
      promotional activities PDF FILE




                                                    7
66.   FDA Warning Letter Bayer RE: Avelox false
      and misleading press release PDF FILE

67.   FDA Warning Letter Bayer RE: Cipro Eye Drops Activities and promotional material in violation
      of statues PDF FILE

68.   FDA Warning Letter Bristol Meyers Squibb RE: Tequin cease distribution of
      false and misleading statements regarding this product on web site PDF FILE

69.   FDA Warning Letter R.W. Johnson RE: Floxin promotional slide kit in
      violation of statues; misleading and not submitted for FDA approval prior to distribution PDF
      FILE

70.   FDA Warning Letter Allergan Pharmacueticals RE: Ocuflux False and
      misleading claims regarding superior effectiveness PDF FILE

71.   FDA Warning Letter Allergan Pharmacueticals RE: Ocuflux False and
      misleading claims regarding superior effectiveness 2nd warning PDF FILE

72.   FDA Warning Letter GlaxoWellcome RE: Raxar Issuance of press releases in violation of statue
      false and misleading information PDF FILE

73.   Warning Letter to Bayer regarding Avelox misrepresentation PDF FILE

74.   Warning Letter to Bayer regarding manufacturing facilties PDF FILE

75.   Warning Letter to Bayer regarding Cipro misrepresentation PDF FILE

76.   FDA Warning Letter Brisol-Meyer Squibb RE: Tequin - Cease distribution of false and
      misleading messages on current website. JPEG FILE

77.   FDA Warning Letter Santen RE: Levofloxacin ophthalmic solutions - Cease promoting drug for
      unapproved use. JPEG FILE

78.   EPA TOXICOLOGICAL REVIEW OF QUINOLINE (CAS No. 91-22-5) PDF FILE

79.   Division of Special Pathogen and Immunologic Drug Products
      Summary of Clinical Review of Studies Submitted in Response to a Pediatric Written Request
      Applications:
               19-537/S-049, ciprofloxacin tablets
               20-780/S-013, ciprofloxacin oral suspension
               19-847/S-027, ciprofloxacin IV 10 mg/mL
               19-857/S-031, ciprofloxacin IV 5% dextrose
      Applicant: Bayer Corporation, Pharmaceutical Division
      Established: Ciprofloxacin PDF FILE

80.   Center for Drug Evaluation and Research Approval Package for
      Levaquin NDA 20-635 PDF FILE

81.   Center for Drug Evaluation and Research Approval Package for
      Levaquin NDA 020-634/S04 and 020635/S03 PDF FILE

82.   AVELOX ® (moxifloxacin hydrochloride) Tablets Final Draft
      Package Insert PDF FILE




                                                  8
83.   Norofloxacin monograph September 1999 PDF FILE

84.   Avelox monograph 12/10/99 PDF FILE

85.   Levaquin monograph January 2002 PDF FILE

86.   Floxin monograph 1998 PDF FILE

87.   Ciprofloxacin monograph 10/2000 PDF FILE

88.   Sitafloxacin ®, drug information March 2000 PDF FILE

89.   Maxaquin ® (lomefloxacin hydrochloride), drug
      information May 1999 PDF FILE

90.   Enoxacin®, drug information PDF FILE

91.   Ciprofloxacin Package Insert January 2004 PDF FILE

92.   Avelox Package Insert October 2003 PDF FILE

93.   60 Day Cipro Study Antimicrobial Postexposure Prophylaxis for Anthrax: Adverse Events and
      Adherence October 2002 PDF FILE

94.   Acute oral toxicity of the new quinolone antibacterial agent levofloxacin in mice, rats and
      monkeys.
      Kato M, Furuhama K, Yoshida M, Akahane K, Takayama S.
      Drug Safety Research Center, Daiichi Pharmaceutical Co., Ltd., Tokyo, Japan.

95.   Arzneimittelforschung. 1992 Mar;43(3A):408-18. General pharmacology of the new quinolone
      antibacterial agent levofloxacin.
      Takasuna K, Kasai Y, Usui C, Takahashi M, Hirohashi M, Tamura K, Takayama S.
      Drug Safety Research Center, Daiichi Pharmaceutical Co., Ltd., Tokyo, Japan.

96.   4-Quinolones cause a selective loss of mitochondrial DNA from mouse L1210 leukemia cells.

97.   Acute oral toxicity of the new quinolone antibacterial agent levofloxacin in mice, rats and
      monkeys. Kato M, Furuhama K, Yoshida M, Akahane K, Takayama S. Drug Safety Research
      Center, Daiichi Pharmaceutical Co., Ltd., Tokyo, Japan.




                                                   9

				
DOCUMENT INFO
Description: Retail Sales Figures document sample